PetMed Express, Inc. (NASDAQ:PETS) Receives Consensus Recommendation of “Hold” from Analysts

PetMed Express, Inc. (NASDAQ:PETS – Get Rating) has been given an average recommendation of “Hold” by the six brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $27.00.

PETS has been the topic of a number of analyst reports. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $32.00 price target on the stock in a research note on Thursday, January 20th. Morgan Stanley decreased their price target on PetMed Express from $25.00 to $21.00 and set an “underweight” rating on the stock in a research note on Tuesday, January 25th. StockNews.com initiated coverage on PetMed Express in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Zacks Investment Research upgraded PetMed Express from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 30th.

Shares of PETS stock opened at $24.15 on Monday. The business’s 50 day moving average is $26.27 and its two-hundred day moving average is $26.61. PetMed Express has a twelve month low of $21.64 and a twelve month high of $46.67. The company has a market capitalization of $506.64 million, a P/E ratio of 22.36 and a beta of 0.45.

PetMed Express (NASDAQ:PETS – Get Rating) last announced its earnings results on Monday, January 24th. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.09). PetMed Express had a net margin of 7.83% and a return on equity of 16.00%. The company had revenue of $60.72 million during the quarter, compared to analysts’ expectations of $61.90 million. During the same quarter last year, the business posted $0.38 earnings per share. Research analysts expect that PetMed Express will post 1.06 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Fisher Asset Management LLC boosted its position in PetMed Express by 98.9% during the fourth quarter. Fisher Asset Management LLC now owns 87,935 shares of the company’s stock worth $2,221,000 after purchasing an additional 43,717 shares in the last quarter. WBI Investments Inc. purchased a new stake in PetMed Express during the fourth quarter worth $513,000. Allianz Asset Management GmbH boosted its position in PetMed Express by 38.7% during the third quarter. Allianz Asset Management GmbH now owns 380,630 shares of the company’s stock worth $10,228,000 after purchasing an additional 106,275 shares in the last quarter. Maryland State Retirement & Pension System purchased a new stake in PetMed Express during the third quarter worth $219,000. Finally, Atom Investors LP boosted its position in PetMed Express by 255.9% during the third quarter. Atom Investors LP now owns 23,281 shares of the company’s stock worth $626,000 after purchasing an additional 16,740 shares in the last quarter. Institutional investors own 80.50% of the company’s stock.

PetMed Express Company Profile (Get Rating)

PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Featured Stories